ClinicalTrials.gg
RecruitingNCT05853796ODYSSEY-nEXTUpdated May 11, 2023

Observational Dutch Young Symptomatic StrokE studY - nEXT

An observational study in Ischemic Stroke, Stroke in the Young and Cardiovascular Diseases, sponsored by Radboud University Medical Center. Recruiting at 6 sites in Netherlands. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2023-05-11.

Sponsored by Radboud University Medical Center · Observational

How we know

From the registry’s dates

  • Started Feb 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
280
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 45 studies in Ischemic Stroke with a site in Netherlands — 14 open to participants now, 17 under way, 2 of them phase 3. Ischemic Stroke · Netherlands.

Planned enrollment
7th of 11
280 · median 300
Started
2023
with 5 others
Observational
11 of 45
5 open now
Primary completion
2027-01
later than 9 of 16 live
Registered
33rd of 45
by date

Among the 45 studies in Ischemic Stroke with a site in Netherlands, this one is the 7th largest by planned enrollment of the 11 observational ones that give a count, is one of 6 that started in 2023, is one of 11 observational ones, reaches primary completion later than 9 of the 16 other live ones, and was the 33rd registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

14 of the 45 studies in Ischemic Stroke with a site in Netherlands are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Ischemic Stroke with a site in Netherlands, or all of them as a file.
02

Study summary

BACKGROUND: Worldwide, 2 million patients aged 18-50 years suffer an ischemic stroke each year with an increasing trend over the past decade due to yet unknown reasons. Whereas prognosis and antithrombotic treatment in older patients with cardiovascular disease are among the best studied topics in clinical medicine, this does not hold true for patients at young age. It is of great importance to treat these patient groups correctly to prevent recurrence and bleeding complications. However, previous research have shown that there is a long-term increased risk of recurrent ischemic events despite the secondary prevention and a subsequent increased bleeding risk. To tailor effective antithrombotic therapy to the individual patient, it is essential to understand the underlying pathogenesis and identify modifiable risk factors in young patients for recurrence or bleeding. It is thought that abnormalities of hemostasis may play a key role in early-onset ischemic stroke. First, prothrombotic conditions are associated with an increased risk for ischemic stroke at young age. In addition, disturbance of the hemostatic balance due to one or several triggers can activate the coagulation cascade, which on its turn can lead or contribute to clot formation and subsequent arterial occlusion. In previous study, there were indications that trigger factors such as fever and/or an infection in the days prior to the stroke may play a role in the pathogenesis. This suggests that an interaction between inflammation, endothelial damage and coagulation may lead to the formation of a clot. In this observational study we aim to investigate the role of the immune system, endothelial damage and coagulation in the pathogenesis and prognosis of stroke in young patients.

OBJECTIVE: To investigate the role of hemostasis, inflammation and endothelial activation in the etiology and prognosis in an acute ischemic stroke (or TIA) in young stroke patients.

STUDY DESIGN: Multicentre prospective observational study

STUDY POPULATION:

All patients aged between 18 and 50 years old with a first-ever ischemic stroke or TIA who are admitted to the neurology ward or seen at the outpatient clinic of one of the participating centers.

Main exclusion criteria are: history of clinical TIA, ischemic stroke or intracerebral hemorrhage. A intracerebral hemorrhage resulting from trauma, known aneurysm or underlying intracerebral malignancy. A venous infarction, retinal infarction and amourosis fugax. Inadequate control of the Dutch language to reliably sign an informed consent from and/or participate in the follow-up. Patients are excluded if they have a contra indication for 3T MRI.

In addition 60 healthy controls (18-50 years old) will be included.

MAIN STUDY ENDPOINTS:

  1. Baseline and 3 months coagulation profile:

    Whole blood and platelet poor plasma thrombin generation, platelet function tests, and coagulation biomarkers, screening for thrombophilia.

  2. Baseline and 3 months inflammation/endothelial activation profile:

    Cytokines/chemokines, expression of receptors/cofactors related to hemostasis on peripheral blood mononuclear cells (PBMCs), stimulation tests of PBMC's to assess trained immunity.

  3. Vessel wall enhancement on 3 Tesla MRI
  4. Questionnaire trigger factors
03

Conditions studied

  • Ischemic Stroke
  • Stroke in the Young
  • Cardiovascular Diseases
  • Cerebrovascular Disorders
  • Embolism and Thrombosis
  • Thrombophilia
  • Coagulation
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Sampling method
Probability sample

Study population

Patients aged 18 to 49 hospitalized due to first-ever imaging-positive ischemic stroke or transient ischemic attack.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with a first-ever (TIA) or acute ischemic stroke aged between 18 and 50 years old
  • For this study, acute stroke is defined as "occurence of acute neurological deficit lasting more than 24 hours, with confirmation on imaging (CT(-a) or MR(-a))".TIA is defined as "occurence of acute neurological deficit lasting less than 24 hours with confirmation of ischemia on MRI).
  • Patients have a kidney function >30ml/min.

Exclusion criteria

Exclusion Criteria:

  • A history of clinical , ischemic stroke or intracerebral hemorrhage
  • A intracerebral hemorrhage resulting from trauma, known aneurysm or underlying intracerebral .
  • A venous infarction, retinal infarction or amourosis fugax.
  • Inadequate control of the Dutch language to reliably sign an from and/or participate in the follow-up
  • Patients are excluded if they have a contra indication for 3T MRI.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
280 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Patients with acute ischemic stroke at young age (18-50 years)

    Patients aged 18 to 50 years with first-ever ischemic stroke or transient ischemic attack.

  • Healthy controls

    Healthy controls (aged 18 to 50 years) without cardiovascular diseases in their medical history. Subjects age- and gender-matched to patients

06

What researchers measure

Primary outcomes

  1. Difference of concentration biomarkers and coagulation assays between patients and controls

    Biomarkers and assays of coagulation, inflammation and endothelium activation

    Time frame: At baseline and 3 month visit

Secondary outcomes

  1. Nonfatal or fatal recurrent cardiovascular (ischemic) events

    Ischemic stroke or transient ischemic attack, acute coronary syndrome, peripheral artery disease

    Time frame: 10 years

  2. Recurrent venous thrombotic events

    Deep venous thrombosis, pulmonary embolism, cerebral venous sinus thrombosis

    Time frame: 10 years

  3. Death from any cause

    Time frame: 10 years

  4. Malignancy

    Time frame: 10 years

  5. Bleeding complications

    Minor and major bleeding complications

    Time frame: 10 years

  6. Vessel wall imaging on 3T MRI

    Detection of vessel wall enhancement on MRI in young stroke patients

    Time frame: At baseline

Other outcomes

  1. Modified Rankin Scale

    Functional outcome will be assessed with modified Rankin Scale

    Time frame: at 3-month visit and at annual follow-up contacts from year 1 to year 10

  2. Functional outcome will be assessed with Barthel Index

    Time frame: at 3-month visit and at annual follow-up contacts from year 1 to year 10.

  3. Coping strategies

    Questionnaire about different strategies to cope with major setbacks.

    Time frame: at 3 months visit and 6 months

  4. Subjective cognitive outcome

    Subjective cognition will be assessed with an electronic questionnaire

    Time frame: at 6-month follow-up

07

Study locations

1 of 6 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Jan 2027, 46 months after the start.

Of 401 non-industry observational studies under Ischemic Stroke, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 140. This study's planned 46 months is below that.

Counting every sponsor, half of 443 studies reached it within 53 months; a quarter within 24 and three quarters within 127.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2023
First posted
May 11, 2023
StartActual
Feb 6, 2023
Primary completionEst.
Jan 1, 2027
CompletionEst.
Jan 1, 2037
Last update
May 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05853796
Collaborators
Synapse bv
Responsible party
Sponsor
First posted
May 11, 2023
Start date
Feb 6, 2023
Primary completion
Jan 1, 2027 (estimated)
Completion
Jan 1, 2037 (estimated)
Last update
May 11, 2023

Study contacts

Frank-Erik De Leeuw, Prof.
Contact
frankerik.deleeuw@radboudumc.nl
0031650200314
Janneke Spiegelenberg, MD
Contact
janneke.spiegelenberg@radboudumc.nl

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion